Ca2+/calmodulin-dependent protein kinase II

Cardurion Pharmaceuticals to Provide Update on CaMKII Inhibitor Program at the American Heart Association’s Scientific Sessions 2023

Retrieved on: 
Tuesday, November 7, 2023
Health, General Health, Research, Science, Pharmaceutical, Cardiology, Biotechnology, Rat, Survival, Therapy, Calcium/calmodulin-dependent protein kinase type II subunit alpha, CPVT, Mortality, Atrial fibrillation, Doctor of Philosophy, Cell, Phosphorylation, American Heart, Ca2+/calmodulin-dependent protein kinase II, AHA, Heart failure, Calsequestrin, Pharmaceutical industry

Cardurion is the first company to evaluate a CaMKII inhibitor in clinical testing.

Key Points: 
  • Cardurion is the first company to evaluate a CaMKII inhibitor in clinical testing.
  • The Company will present data on two of its highly selective and potent CaMKII inhibitors, CRD-2015 and CRD-2959, in a preclinical model of heart failure.
  • Both CaMKII inhibitors prolonged survival in the calsequestrin transgenic heart failure model, which is characterized by a severe dilated cardiomyopathy and early mortality.
  • The Company next plans to expand this research into more common cardiovascular diseases, such as heart failure and atrial fibrillation.

Cardurion Pharmaceuticals Welcomes Emma Reeve as Independent Board Director and Audit Chair

Retrieved on: 
Wednesday, October 4, 2023
Science, Cardiology, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Constellation, Bachelor of Science, PTC Therapeutics, University, University of London, Therapy, MorphoSys, South African Institute of Chartered Accountants, Cardiovascular disease, Parexel, Bristol Myers Squibb, Sale, Editas Medicine, PDE9, Inotek Pharmaceuticals, Novartis, Patient, Trustee, Risk, Imperial College London, Merck, Ca2+/calmodulin-dependent protein kinase II, Pharmaceutical industry

Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of Emma Reeve as an independent board director and audit chair.

Key Points: 
  • Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of Emma Reeve as an independent board director and audit chair.
  • Ms. Reeve brings to Cardurion more than 25 years of global financial leadership and board experience across pharmaceutical, medical device and biopharma companies.
  • As a seasoned life sciences executive with deep expertise in finance, capital markets and corporate strategy, Emma brings tremendous perspective to Cardurion’s Board,” said Michael E. Mendelsohn, M.D., Founder and Chairman of Cardurion.
  • “I am impressed with the bold and innovative approach Cardurion is taking to help patients suffering from and at risk for cardiovascular disease,” said Ms. Reeve.

Neurexis Therapeutics: New Discoveries Could Revolutionize Treatment of Alzheimer's and Other Neurological Conditions

Retrieved on: 
Wednesday, September 20, 2023
Neuroprotection, Learning, Myenteric plexus, University of Colorado School of Medicine, University, Nature, Research, Doctor of Philosophy, Dementia, DSM-IV codes, LTP, Colorado School of Public Health, Patient, Therapy, Memory, Medicine, Ca2+/calmodulin-dependent protein kinase II, Pharmaceutical industry, Alzheimer's disease, Pharmacology

AURORA, Colo., Sept. 20, 2023 /PRNewswire-PRWeb/ -- Neurexis Therapeutics, a biotechnology company committed to reshaping the landscape of neuroprotection, is excited to highlight recent groundbreaking research that could unlock new avenues for Alzheimer's disease and other brain disease therapies. The findings made by scientists at the University of Colorado Anschutz Medical Campus shed light on memory mechanisms that could hold the key to transforming the treatment of Alzheimer's disease and related conditions.

Key Points: 
  • The findings made by scientists at the University of Colorado Anschutz Medical Campus shed light on memory mechanisms that could hold the key to transforming the treatment of Alzheimer's disease and related conditions.
  • In a study published in the prestigious journal Nature , researchers from the University of Colorado have upended the conventional wisdom on the mechanisms governing learning and memory.
  • According to Michael Artinger, PhD, CEO of Neurexis Therapeutics, "CaMKII is the target of our peptide inhibitor tatCN19o, which has demonstrated robust neuroprotection in multiple disease models.
  • The results from Dr. Bayer's lab suggest there is a significant opportunity for this therapeutic to dramatically improve the outlook for millions of people impacted by Alzheimer's disease."

Kanazawa University research: Experiments provide insights into the molecular mechanism for memory and learning

Retrieved on: 
Monday, July 3, 2023
Learning, Neuron, Rat, PO3, Phosphorylation, Serine, Science Advances, PO4, Rotation, Mammal, OH, Hydra, ATP, Polymerization, Enzyme, Protein kinase, CAMK, Krasnow Institute for Advanced Study, Dicarboxylic acid, International Union of Physiological Sciences, Protein, National Institute for Physiological Sciences, Japan, The Graduate University for Advanced Studies, Postgraduate education, Memory, Calmodulin, AFM, Synapse, Kanazawa University, Sulfur, Microscope, Science, Ca2+/calmodulin-dependent protein kinase II

The strength of these connections varies – for instance strengthening or weakening depending on the signals received and how.

Key Points: 
  • The strength of these connections varies – for instance strengthening or weakening depending on the signals received and how.
  • This synaptic 'plasticity' underlies learning and memory, and the Ca2+/calmodulin-dependent protein kinase II (CaMKII) is known to play a key role.
  • CaMKII is common to a vast range of species from mammals like rats to older, non-mammalian species like the roundworms (C. elegans) and hydra.
  • The type two Ca2+/calmodulin-dependent protein kinases are multifunctional and are involved in neurotransmitter secretion, transcription factor regulation, and glycogen metabolism.

Kanazawa University research: Experiments provide insights into the molecular mechanism for memory and learning

Retrieved on: 
Monday, July 3, 2023
Learning, Neuron, Rat, PO3, Phosphorylation, Serine, Science Advances, PO4, Rotation, Mammal, OH, Hydra, ATP, Polymerization, Enzyme, Protein kinase, CAMK, Krasnow Institute for Advanced Study, Dicarboxylic acid, International Union of Physiological Sciences, Protein, National Institute for Physiological Sciences, Japan, The Graduate University for Advanced Studies, Postgraduate education, Memory, Calmodulin, AFM, Synapse, Kanazawa University, Sulfur, Microscope, Science, Ca2+/calmodulin-dependent protein kinase II

The strength of these connections varies – for instance strengthening or weakening depending on the signals received and how.

Key Points: 
  • The strength of these connections varies – for instance strengthening or weakening depending on the signals received and how.
  • This synaptic 'plasticity' underlies learning and memory, and the Ca2+/calmodulin-dependent protein kinase II (CaMKII) is known to play a key role.
  • CaMKII is common to a vast range of species from mammals like rats to older, non-mammalian species like the roundworms (C. elegans) and hydra.
  • The type two Ca2+/calmodulin-dependent protein kinases are multifunctional and are involved in neurotransmitter secretion, transcription factor regulation, and glycogen metabolism.

Cardurion Pharmaceuticals Strengthens Leadership Team with Appointment of Elizabeth Radcliffe as Chief Financial Officer

Retrieved on: 
Thursday, January 19, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Cardiovascular disease, Organic chemistry, Harvard University, Agios Pharmaceuticals, Degenerative disease, Drug development, PDE9, Census-designated place, Therapy, Yale University, Sale, Ca2+/calmodulin-dependent protein kinase II, MBA, GSK, Arrakis Therapeutics, Management, Biogen, Chemistry

Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of Elizabeth Radcliffe as Chief Financial Officer.

Key Points: 
  • Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of Elizabeth Radcliffe as Chief Financial Officer.
  • A seasoned strategic finance leader, Ms. Radcliffe brings to Cardurion more than two decades of broad industry experience and company-building, including financial leadership roles at Affinivax, Agios Pharmaceuticals, Arrakis Therapeutics, and Biogen.
  • Ms. Radcliffe has significant experience across a range of biopharmaceutical R&D, commercial and business operations at large and small organizations, including both public and private companies.
  • Ms. Radcliffe’s earlier leadership roles included serving as Vice President, Finance and Strategy and Treasurer at Arrakis Therapeutics, and as Vice President, Financial Planning & Analysis at Agios Pharmaceuticals.

CODA Biotherapeutics Announces Preclinical Data From Epilepsy Program to be Presented at American Society of Gene & Cell Therapy 25th Annual Meeting

Retrieved on: 
Thursday, May 5, 2022
SYN, World, Journal of Pain Research, Epilepsy, Neuron, Population, Lists of diseases, Brain, Plasmid, National Institute of Neurological Disorders and Stroke, Neuropathic pain, Digital polymerase chain reaction, Company, HeLa, National Institute, Cytomegalovirus, ITRS, AAV, CA, World Health Organization, Ca2+/calmodulin-dependent protein kinase II, Male, CODA, Seizure, DdPCR, Epilepsy Foundation, ELISA, CAG, Center, Journal, Disability, Social isolation, Quality of life, Movement disorders, LGIC, Disease, Anticonvulsant, Patient, Peripheral neuropathy, Stroke, Polyadenylation, RNA transfection, Social stigma, Centers for Disease Control and Prevention, Cell, CMV, Multimedia, Cassette tape, Poultry, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., May 5, 2022 /PRNewswire/ -- CODA Biotherapeutics, Inc. ("CODA"), a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform to treat intractable neurological disorders, today announced that preclinical data from the Company's focal epilepsy program will be featured as a poster presentation at the American Society of Gene & Cell Therapy 25th Annual Meeting being held virtually and in person, May 16-19, 2022, in Washington, D.C.

Key Points: 
  • Analysis by ddPCR revealed high levels of LGIC mRNA expression from CaMKII- and Syn-driven cassettes, which were comparable to the strong, ubiquitous CAG promoter.
  • The Epilepsy Foundation estimates that one-third of people with epilepsy live with uncontrollable seizures because no available treatments are effective.
  • CODA Biotherapeutics is developing a paradigm-shifting gene therapy approach by deploying a chemogenetic strategy for treating neurological disorders.
  • CODA Biotherapeutics, Inc., is a preclinical-stage biopharmaceutical company developing an innovative gene therapy platform to treat intractable neurological disorders, with an initial focus on epilepsy, movement disorders, and neuropathic pain.

Cardurion Pharmaceuticals Enhances Leadership Team with Appointment of Marcia Moore as Chief Operating Officer

Retrieved on: 
Wednesday, February 16, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, NASDAQ, Cancer Prevention and Research Institute of Texas, Patient, Research institute, PDE9, Cancer prevention, Company, Ca2+/calmodulin-dependent protein kinase II, Degenerative disease, Bain Capital, IND, Strategic Operations, Heart failure, Bristol Myers Squibb, Therapy, Strategic planning, Cardiovascular disease, Yale University, Growth, Drug discovery, Bates College, Alexion Pharmaceuticals, Drug development, Pharmaceutical industry

Cardurion Pharmaceuticals, Inc. (Cardurion or the Company), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced the appointment of Marcia Moore as Chief Operating Officer.

Key Points: 
  • Cardurion Pharmaceuticals, Inc. (Cardurion or the Company), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced the appointment of Marcia Moore as Chief Operating Officer.
  • Ms. Moore joins Cardurion from Arvinas, Inc., bringing more than three decades of pharmaceutical and biotechnology industry experience in clinical development, project management and strategic planning.
  • Ms. Moore has significant experience working across all phases of the drug development process, including IND-enabling activities, clinical trials and the post-marketing setting.
  • Most recently, she was Senior Vice President, Strategic Operations at Arvinas (NASDAQ: ARVN), serving as a key member of the executive leadership team defining the growth strategy.

Cardurion Pharmaceuticals Announces Investment of up to $300 Million From Bain Capital

Retrieved on: 
Wednesday, October 27, 2021
Banking, Research, Other Health, General Health, Professional Services, Pharmaceutical, Science, Other Professional Services, Cardiology, Biotechnology, Finance, Health, Other Science, Science, MD, Technology, PDE9, Bain Capital, Drug development, Polaris Partners, Partnership, Health, Patient, Drug discovery, Cardiovascular disease, LP, Takeda Pharmaceutical Company, Ca2+/calmodulin-dependent protein kinase II, Company, Disease, Program, Mortality, Therapy, Doctor of Philosophy, Heart failure, Degenerative disease, Pharmaceutical industry, Cardurion Pharmaceuticals, Bain Capital, CARDURION PHARMACEUTICALS, BAIN CAPITAL

Cardurion Pharmaceuticals, Inc. (Cardurion or the Company), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced it has received a private investment of up to $300 million from Bain Capital Life Sciences and Bain Capital Private Equity.

Key Points: 
  • Cardurion Pharmaceuticals, Inc. (Cardurion or the Company), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced it has received a private investment of up to $300 million from Bain Capital Life Sciences and Bain Capital Private Equity.
  • Bain Capital joins existing investors, Takeda Pharmaceuticals and Polaris Partners, in supporting the evolution of Cardurion into a leading cardiovascular biotechnology company.
  • We could not be more excited to welcome Bain Capital as investors in this transformational milestone for Cardurion, said Peter Lawrence, Chief Executive Officer of Cardurion.
  • In conjunction with Bain Capitals investment, Koppel and Nicholas Downing, MD, a Principal at Bain Capital Life Sciences, will join the Cardurion Board of Directors.